Practical aspects of targeting IL-6 in COVID-19 disease #MMPMID32409439
Calabrese C; Rajendram P; Sacha GL; Calabrese L
Cleve Clin J Med 2020[Oct]; ä (ä): ä PMID32409439show ga
Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been used often in the intensive care setting, and new data question their efficacy. This brief review provides practical information on their administration and safety.